Aug 21 (Reuters) - Hikma Pharmaceuticals said itexpected full-year revenue to rise 20 percent as strong sales ofits generic antibiotic doxycycline in the United States continueand reported a 93 percent jump in first-half profit.
The company, which makes and sells branded and genericdrugs, said profit before tax rose to $111.6 million in the sixmonths ended June 30, from $57.8 million a year earlier.
On an adjusted basis, Hikma's pretax profit rose 158percent.
Revenue increased 20 percent to $638.3 million.
Hikma shares closed at 1090 pence on Tuesday on the LondonStock Exchange.